Morgan Stanley
KYTX icon

Morgan Stanley’s Kyverna Therapeutics KYTX Stock Holding History

Morgan Stanley’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.43M Sell
977,289
-25,206
-3% -$210K ﹤0.01% 3708
2025
Q4 		$9.42M Buy
1,002,495
+828,292
+475% +$6.15M ﹤0.01% 3665
2025
Q3 		$1.05M Sell
174,203
-27,835
-14% -$111K ﹤0.01% 5153
2025
Q2 		$620K Buy
202,038
+67,128
+50% +$166K ﹤0.01% 5362
2025
Q1 		$260K Sell
134,910
-65,684
-33% -$194K ﹤0.01% 5627
2024
Q4 		$750K Buy
200,594
+80,800
+67% +$387K ﹤0.01% 5234
2024
Q3 		$586K Buy
119,794
+511
+0.4% +$3.94K ﹤0.01% 5323
2024
Q2 		$895K Buy
119,283
+79,352
+199% +$1.21M ﹤0.01% 5027
2024
Q1 		$992K Buy
+39,931
New +$1.11M ﹤0.01% 4958

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Morgan Stanley's KYTX Position: Q1 2026 in Review

Morgan Stanley reduced its Kyverna Therapeutics (KYTX) stake by 2.5% in Q1 2026, selling an estimated $210K and leaving 977,289 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3708.

Morgan Stanley first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $9.42M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Morgan Stanley held 977,289 shares of Kyverna Therapeutics worth $8.43M as of Q1 2026.
  • Morgan Stanley sold 25,206 Kyverna Therapeutics shares in Q1 2026, an estimated $210K.
  • Kyverna Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3708 holding.
  • Morgan Stanley first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Morgan Stanley's Kyverna Therapeutics position peaked at $9.42M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.